Skip to main content
Premium Trial:

Request an Annual Quote

Beckman Coulter Life Sciences Acquires Labcyte

NEW YORK (GenomeWeb) — Beckman Coulter Life Sciences announced today that it has acquired privately held liquid handling firm Labcyte.

Based in San Jose, California, Labcyte has developed an acoustic droplet ejection technology called Echo that uses sound energy for the contactless transfer of samples and reagents. Specific terms of the acquisition were not disclosed.

"Labcyte's unique product portfolio complements our existing liquid handling and laboratory automation business," Beckman Coulter Life Sciences President Jonathan Pratt said in a statement. "It provides new opportunities to develop and enhance time-saving solutions for customer workflows."

With the acquisition, Labcyte will be integrated into Indianapolis-based Beckman Coulter Life Sciences, which is a subsidiary of Danaher.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.